Substituted triazolinones, triazolinethiones, and triazolinimines as
申请人:Merck & Co., Inc.
公开号:US05411980A1
公开(公告)日:1995-05-02
There are disclosed new substituted triazolinone, triazolinethione, and triazolinimine compounds which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1## wherein G is R.sup.1 or ##STR2##
Synthesis, insecticidal evaluation and mode of action of novel anthranilic diamide derivatives containing sulfur moiety as potential ryanodine receptor activators
作者:Feng-Yun Li、Yuan-Hong Wang、Jing-Bo Liu、Yu-Xin Li、Zheng-Ming Li
DOI:10.1016/j.bmc.2019.01.009
日期:2019.3
Anthranilic diamide insecticide could control lepidopteran pests by selectively binding and activating insect ryanodine receptors (RyRs), and the unique mode of action is different from other conventional insecticides. In order to discover new anthranilic diamide insecticide as ryanodine receptors activators, a series of 11 novel anthranilic diamides derivatives (Ia-k) were synthesized and confirmed
Substituted triazolinone compounds are angiotensin II antagonists and therefore useful in the treatment of hypertension, and related cardiovascular disorders and ocular hypertension. These compounds have the general formula:
取代的三唑啉酮化合物是血管紧张素 II 拮抗剂,因此可用于治疗高血压、相关心血管疾病和眼压过高。这些化合物的通式如下
Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1 and AT2 Subtypes
作者:Linda L. Chang、Wallace T. Ashton、Kelly L. Flanagan、Tsing-Bau Chen、Stacey S. O'Malley、Gloria J. Zingaro、Peter K. S. Siegl、Salah D. Kivlighn、Victor J. Lotti
DOI:10.1021/jm00052a006
日期:1994.12
Angiotensin II (AII), the endogenous peptide Ligand of the AII receptor, has equivalent high affinity for both the AT(1) and AT(2) receptor subtypes while most of the reported nonpeptide AII antagonists are AT(1)-selective. In an effort to identify dual AT(1)/AT(2) nonpeptide AII antagonists, we have pursued modifications of previously prepared trisubstituted 1,2,4-triazolinone biphenylsulfonamides which exhibited subnanomolar in vitro AT(1) (rabbit aorta) AII antagonism and AT(2) (rat midbrain) IC50 values of <40 nM. Present results show that a suitable amide (or reversed amide) side chain appropriately positioned on the N-2-aryl group of these compounds gave >15-fold enhancement in AT(2) binding affinity without sacrificing nanomolar AT(1) potency (IC50). This added amide, combined with an appropriate choice of the N-substituent on the sulfonamide and the ortho substituent on the N-2-aryl group, led to an analogue (46, L-163,- 007) which exhibited subnanomolar AT(1) binding affinity and an AT(2)/AT(1) IC50 ratio of 3. This compound showed excellent iv activity at 1 mg/kg and oral efficacy at 3 mg/kg with >6 h duration in a conscious rat model. Available data suggest that the newly introduced amide side chain, mandatory for low nanomolar binding affinity at the AT(2) receptor, is well-tolerated by the AT(1) receptor and has minimal effect on the in vivo properties of these molecules.